Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral Wegovy. Elsewhere, Regeneron inked a drug price deal and two companies announced leadership changes.

Tolebrutinib, which the FDA recently turned back due to safety concerns, received a positive recommendation that positions ...

Pharmaceutical companies already use artificial intelligence for tasks like optimizing clinical trials, identifying drug targets and developing predictive models for risk detection. But AI’s next ...

Worth up to $7 billion, Lilly’s second recent acquisition of a company in the space is centered around a cell therapy that’s ...

Patients who'd seen substantial hair regrowth in the first part of Nektar’s trial had a "deepening" treatment response, ...

Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug development.

Republicans largely praised the HHS secretary’s track record during a marathon of House hearings last week, but some raised ...

The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But ...

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s ...

On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines ...

The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and ...